Joel Greenblatt’s Catalyst Pharmaceutical CPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-41,216
Closed -$1.3M – 1891
2026
Q2
$1.3M Sell
41,216
-20,155
-33% -$595K ﹤0.01% 1293
2026
Q1
$1.52M Sell
61,371
-594
-1% -$14.2K ﹤0.01% 1188
2025
Q4
$1.45M Sell
61,965
-79,378
-56% -$1.77M 0.01% 1145
2025
Q3
$2.78M Buy
141,343
+31,618
+29% +$650K 0.01% 915
2025
Q2
$2.38M Buy
109,725
+62,416
+132% +$1.47M 0.01% 870
2025
Q1
$1.15M Buy
47,309
+8,356
+21% +$188K 0.01% 963
2024
Q4
$813K Buy
38,953
+2,812
+8% +$60.4K 0.01% 971
2024
Q3
$718K Buy
36,141
+2,444
+7% +$45.3K 0.01% 997
2024
Q2
$522K Sell
33,697
-1,491
-4% -$23.2K 0.01% 1075
2024
Q1
$561K Sell
35,188
-2,314
-6% -$34.9K 0.01% 1004
2023
Q4
$630K Sell
37,502
-76,504
-67% -$1.05M 0.01% 920
2023
Q3
$1.33M Buy
114,006
+3,532
+3% +$47.2K 0.03% 681
2023
Q2
$1.48M Sell
110,474
-28,977
-21% -$417K 0.03% 641
2023
Q1
$2.31M Buy
139,451
+120,406
+632% +$1.99M 0.06% 468
2022
Q4
$354K Sell
19,045
-31,130
-62% -$479K 0.01% 999
2022
Q3
$644K Buy
+50,175
New +$595K 0.02% 789
2020
Q4
– Sell
-32,653
Closed -$97K – 1015
2020
Q3
$97K Sell
32,653
-37,219
-53% -$146K ﹤0.01% 983
2020
Q2
$323K Sell
69,872
-57,062
-45% -$256K 0.01% 847
2020
Q1
$489K Buy
126,934
+90,420
+248% +$371K 0.01% 725
2019
Q4
$137K Sell
36,514
-3,306
-8% -$15.5K ﹤0.01% 1065
2019
Q3
$211K Buy
+39,820
New +$212K ﹤0.01% 1001

Other funds holding CPRX

Joel Greenblatt's CPRX Position: Q3 2026 in Review

Joel Greenblatt sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 41,216 shares — an estimated $1.3M sold.

Joel Greenblatt first reported a position in CPRX in Q3 2019 and held it in 21 quarters. The position peaked at $2.78M in Q3 2025. 3 funds tracked by Wall St. Rank hold CPRX as of Q3 2026.

  • Joel Greenblatt reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
  • Joel Greenblatt sold 41,216 Catalyst Pharmaceutical shares in Q3 2026, an estimated $1.3M.
  • Joel Greenblatt first reported a position in Catalyst Pharmaceutical in Q3 2019 and held it in 21 quarters.
  • Joel Greenblatt's Catalyst Pharmaceutical position peaked at $2.78M in Q3 2025.
  • 3 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.

Based on Gotham Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.